Come to this landmark event to meet, learn and partner with colleagues who are effectively proclaiming opioid dependence as a treatable disease.

Wyndham Palace Resort & Spa
Orlando, FL
Dear Friends & Colleagues:

The American Association for the Treatment of Opioid Dependence 20th Anniversary National Conference plans are taking shape as the October 16-20, 2004, dates are approaching. At this stage it is clear that the 2004 Conference will be exciting, informative, and (being in Orlando) FUN.

The Conference gets off to an early start with the Pre-Conference Presentations scheduled for October 16 and 17, 2004. Pre-Conference activities will address major areas of interest and concern to our field. Full-day courses offered include Buprenorphine, OTP & Office-Based Treatment of Opioid Dependence; a training course leading to Certification of Methadone Advocates (CMA); and an updated Course for Clinicians. Other Pre-Conference sessions include the European Opiate Addiction Treatment Association, Top Accreditation Challenges for OTPs, Opioid Treatment in a Corrections Setting, Risk Management in the OTP, and presentations by the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Drug Abuse (NIDA).

At no time in our history have we faced so many changes, advances, and challenges. The content of the Conference is broad to address the needs of many disciplines in a variety of formats including the Plenary and Workshop Sessions. Plenary Sessions will officially open each day of the Conference beginning the morning of Monday, October 18, 2004. The Plenary Sessions will feature government officials, representatives from scientific institutes and drug courts, and other thought-provoking speakers. The Workshop Sessions will incorporate many issues related to opioid dependence including quality improvement, prescription opioid use and abuse, women's treatment issues, and integrating evidence-based treatment approaches within opioid treatment.

In addition to sessions and workshops there will be ample time for networking, perusing the exhibits, and viewing the poster presentations. You may also plan an extra day or two to take advantage of the local attractions, cultural events, and fine dining. I would also like to point out that October offers perhaps the best of Florida's year-round ideal weather.

The Florida Department of Children & Families/Substance Abuse Program Office, the Florida Association for the Treatment of Opioid Dependence, and Colonial Management Group are pleased to serve as hosts for the American Association for the Treatment of Opioid Dependence 20th Anniversary National Conference.

I look forward to seeing you in October!

Sincerely yours,

J. Thomas Payte, MD
Conference Chair, 2004
# Conference at a Glance

<table>
<thead>
<tr>
<th>DAY</th>
<th>DATE</th>
<th>TIME</th>
<th>EVENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saturday</strong></td>
<td><strong>October 16</strong></td>
<td>7:00 AM – 4:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Buprenorphine, OTP &amp; Office-Based Treatment of Opioid Dependence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:30 AM – 5:30 PM</td>
<td>The Certified Methadone Advocate (CMA) Training Course</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>The Top Accreditation Challenges for OTPs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:00 PM – 8:00 PM</td>
<td>American Association for the Treatment of Opioid Dependence Open Board Meeting – Board of Directors</td>
</tr>
<tr>
<td><strong>Sunday</strong></td>
<td><strong>October 17</strong></td>
<td>7:30 AM – 6:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 5:30 PM</td>
<td>Opioid Maintenance Pharmacotherapy: A Course for Clinicians</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 12:00 PM</td>
<td>Opioid Treatment in a Corrections Setting — One Community’s Response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 12:00 PM</td>
<td>New Accreditation Initiative: Shared Visions — New Pathways</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:00 AM – 12:30 PM</td>
<td>State Methadone Authorities Meeting – Closed Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>State Methadone Authorities Meeting – Closed Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>NIDA Clinical Trials Network: Emerging Research Findings to Improve Treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2:00 PM – 5:00 PM</td>
<td>European Opiate Addiction Treatment Association (EUROPAD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5:30 PM – 7:30 PM</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 PM – 8:30 PM</td>
<td>Methadone Anonymous Meetings</td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td><strong>October 18</strong></td>
<td>7:30 AM – 4:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 12:30 PM</td>
<td>Exhibits and Poster Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Opening Plenary Session—National Drug Policy: Reducing Demand by Improving Treatment Access</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 5:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:30 PM – 1:30 PM</td>
<td>Exhibit Hall Closed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Sessions/Hot Topic Roundtables</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 4:30 PM</td>
<td>Exhibits and Poster Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 3:30 PM</td>
<td>Refreshment Break in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:30 PM – 5:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 PM – 8:30 PM</td>
<td>Methadone Anonymous Meetings</td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td><strong>October 19</strong></td>
<td>7:30 AM – 4:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 8:30 AM</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:30 AM – 12:30 PM</td>
<td>Exhibits and Poster Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:45 AM – 10:15 AM</td>
<td>Middle Plenary Session – Research to Practice: Using Evidence-Based Methods in Community Treatment and Drug Court Settings</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10:30 AM – 12:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:00 PM – 1:30 PM</td>
<td>Lunch (on your own)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12:30 PM – 1:30 PM</td>
<td>Exhibit Hall Closed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 3:00 PM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:30 PM – 4:30 PM</td>
<td>Exhibits and Poster Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 3:30 PM</td>
<td>Refreshment Break in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:00 PM – 4:30 PM</td>
<td>Poster Author Session</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 PM – 9:30 PM</td>
<td>Awards Banquet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:30 PM – 10:30 PM</td>
<td>Methadone Anonymous Meetings</td>
</tr>
<tr>
<td><strong>Wednesday</strong></td>
<td><strong>October 20</strong></td>
<td>7:00 AM – 1:00 PM</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7:00 AM – 8:00 AM</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8:00 AM – 9:30 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9:45 AM – 11:15 AM</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:30 AM – 12:45 PM</td>
<td>Closing Plenary Session – Treating the Whole Person: Ensuring the Physical, Mental, and Spiritual Health of Those Recovering from Opioid Dependence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1:00 PM – 3:30 PM</td>
<td>Clinic Tours</td>
</tr>
</tbody>
</table>
PRE-CONFERENCE SESSIONS
Saturday, October 16

BUPRENORPHINE, OTP & OFFICE - BASED TREATMENT of OPIOID DEPENDENCE

Additional Fees Apply – See Below for Registration Information

TIME: 8:00 AM – 5:30 PM

David Fiellin, MD
Yale University School of Medicine
New Haven, CT

Ira Marion, MA
Division of Substance Abuse
Albert Einstein College of Medicine
New York, NY

Leslie Amass, PhD
Friends Research Institute, Inc.
Los Angeles, CA

Lynn Sullivan, MD
Yale University School of Medicine
New Haven, CT

The Drug Addiction Treatment Act of 2000 (PL106-310, Section 3502) permits physicians who are trained or experienced in opioid addiction treatment to obtain waivers to prescribe certain narcotic drugs in Schedule III, IV, or V of the Controlled Substances Act, in their office practices or in an opioid treatment program (OTP) clinic setting, for the treatment of opioid dependence. Both buprenorphine and the combination of buprenorphine with naloxone have been approved by the Food and Drug Administration (FDA) for use in detoxification and maintenance treatment of opioid dependence.

Buprenorphine/naloxone may be dispensed from opioid treatment programs. New federal regulations also allow for the dispensing of buprenorphine/naloxone from opioid treatment programs under the same policies and procedures as methadone.

The target audience includes physicians with experience and/or interest in treating opioid dependence, and medical directors of opioid treatment programs. Physicians, program directors, and masters level health care personnel are also encouraged to participate.

Educational Objectives

After participating in this course, you should be able to describe:

• Models of successfully integrating buprenorphine/naloxone into care in an opioid treatment program
• The prerequisites for a physician to begin to prescribe buprenorphine in office-based practice
• The clinically relevant pharmacological characteristics of buprenorphine
• Factors to consider in determining whether a patient is an appropriate candidate for office based treatment
• Induction and maintenance protocols
• Strategies for integrating psychosocial care with office-based pharmacological treatment
• Treatment strategies for management of acute pain in patients receiving buprenorphine treatment for opioid dependence

As part of the requirements to get the waiver, physicians without specified experience must complete not less than 8 hours of training. Physicians who complete this 8-hour course will meet the training qualification under the new law and will receive a certificate of attendance suitable to send to the Secretary of Health and Human Services along with the request for the waiver. If you give the American Society of Addiction Medicine (ASAM) permission to do so, ASAM will report your name directly to the Secretary of HHS within 4 weeks of the program, if you have completed the full 8 hours, eliminating the need for you to send the certificate of attendance.

Because ASAM will be called upon to confirm that participants have attended a full 8 hours, you must bring a photo identification to show as part of the sign-in process, you must confirm your attendance with your signature at the beginning of both the morning and the afternoon sessions, and you must sign out at the conclusion of the program. Certificates of attendance will be mailed to you within 4 weeks of the program. Note that latecomers may not be eligible for a certificate of attendance if ASAM cannot confirm 8 hours of attendance.

There is a separate registration fee for this Pre-Conference event. Space is limited, and pre-registration is required. For REGISTRATION and CONTINUING MEDICAL EDUCATION INFORMATION please contact the Conference Department at ASAM.

Telephone: (301) 656-3920, Fax: (301) 656-3815, or email@ASAM.org, www.ASAM.org.

Sponsored by the American Society of Addiction Medicine.

Supported by an unrestricted continuing medical educational grant provided by Reckitt Benkiser.
It is the view of the National Alliance of Methadone Advocates (NAMA) that everyone who supports the use of methadone treatment is a potential methadone advocate. We encourage all supporters of methadone treatment, patient and non-patient, to become Certified Methadone Advocates (CMAs) so that all energies directed toward the advancement of methadone treatment produce positive results.

This course fulfills the training requirement for Certification as a Methadone Advocate. It is designed for non-clinicians, and involves 8 hours of rigorous training. The course equips participants with the tools they will need to succeed in the struggle to have methadone maintenance treatment universally accepted as the “gold standard” for addiction treatment.

With these goals in mind the course presentation is as follows:

- **Addiction and Methadone** - scientifically accurate yet in language understandable to the non-clinician.
- **Regulations and Accreditation** - explained by experts from the Center for Substance Abuse and Treatment (CSAT) who understand the systemic complexities.
- **Methadone Mythology** - exposing the myths surrounding methadone treatment.
- **The Certified Methadone Advocate (CMA)** - the mechanism of certification and how it will professionalize those committed to advocacy; includes advocacy on the Net and Methadone Anonymous.
- **Methadone Stigma** - a history of administrative and community prejudice directed at methadone patients, plus analyses of possible solutions.
- **Office Based Treatment Model** - whether Buprenorphine or Methadone, an advance for patients and an administrative hurdle for implementation.

Candidates for certification must register with NAMA prior to the conference. Registration information available at: www.methadone.org/registration.doc

There is a separate registration fee of $100.00 for this pre-conference event. The fee includes all materials, 2005 membership in NAMA, and the application for CMA. Beverages and light snacks served throughout the training. The training will adjourn between 12:00 PM and 1:00 PM. Lunch is not provided.

Sponsored by the National Alliance of Methadone Advocates (NAMA).

Supported by the Substance Abuse and Mental Health Services Administration, Center of Substance Abuse Treatment, and Mallinckrodt, Inc.
This course will serve as a primer for clinicians working in methadone treatment programs. Physicians, physician's assistants, nurses, and other interested personnel who want to learn about opioid treatment practices are encouraged to attend.

The new and expanded curriculum will include epidemiology, opioid pharmacology/neurobiology, evidence-based treatment options, patient assessment/selection, special populations, induction and maintenance protocols, pain management, drug to drug interactions, adverse effects, methadone deaths, managing medical/psychiatric problems, drug testing, regulatory issues, an accreditation update, and an overview of buprenorphine. Participants will receive a comprehensive syllabus and resource materials.

Four experienced opioid treatment medical directors will present, in lecture and question/answer format, focusing on information essential for the clinician to function in an opioid treatment program. To integrate the learning objectives, the presenters will provide case discussions focusing on challenging cases that will facilitate the didactic principles.

The $150.00 registration fee includes a morning coffee service, afternoon luncheon, and the evening’s Welcome Reception.

Sponsored by the American Association for the Treatment of Opioid Dependence in cooperation with the American Academy of Addiction Psychiatry and the American Osteopathic Academy of Addiction Medicine.

Supported by the National Institute on Drug Abuse.
NEW ACCREDITATION INITIATIVE: SHARED VISIONS - NEW PATHWAYS

TIME: 9:00 AM – 12:00 PM

Joint Commission on Accreditation of Healthcare Organizations (JCAHO)

Shared Visions – New Pathways is the culmination of an intensive review and re-design of the Joint Commission’s accreditation process that began in 1999 as a continuous improvement initiative. The result is a complete paradigm shift from a process focused on survey preparation and score achievement to one of continuous systematic and operational improvement by focusing to a greater extent on the provision of safe, high quality care, treatment, and services.

This pre-conference workshop will focus on the changes brought about by Shared Visions – New Pathways including:

- Acquisition and use of more in-depth information about health care organizations to help focus the survey.
- Application of that information to the accreditation process.
- More timely, efficient, and effective communications between JCAHO and health care organizations.
- Reformatting and clarifying standards to focus more directly on safety and quality.
- A more continuous accreditation process to facilitate an organization’s incorporation of the standards into daily operations.
- Accreditation decisions.
- Follow-up after the survey.
- Survey reporting.

At the end of this workshop, participants will be able to:

- Describe changes to the survey process based on Shared Visions – New Pathways.
- Understand how the standards and survey process will be applied to the OTP.

Registration for this workshop is open to all Joint Commission accredited opioid treatment programs. To pre-register for this workshop please contact Megan Marx, Associate Director, at 720-348-0672, or mmarx@jcaho.org.

STATE METHADONE AUTHORITIES’ MEETING (CLOSED SESSION – FOR STATE AND FEDERAL OFFICIALS)

TIME: 9:00 AM – 12:30 PM

Arlene Stanton, PhD
Center for Substance Abuse Treatment
Rockville, MD

Nicholas Reuter, MPH
Center for Substance Abuse Treatment
Rockville, MD

Robert Lubran, MS
Center for Substance Abuse Treatment
Rockville, MD

Ray Hylton, RN
Center for Substance Abuse Treatment
Rockville, MD

C. Todd Rosendale, MA
Center for Substance Abuse Treatment
Rockville, MD

State Methadone Authorities

Center for Substance Abuse Treatment staff and State Methadone Authorities (SMAs) will discuss a variety of topics of interest to both Substance Abuse Mental Health Service Administration (SAMHSA) and the states including the newly released buprenorphine treatment protocols, the impact of the availability of buprenorphine treatment on state policies and procedures, confidentiality issues, the expansion of a pilot project focused on HCV training, and the progress made in defining the issues concerning methadone-related deaths.

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.

STATE METHADONE AUTHORITIES’ MEETING (CLOSED SESSION - FOR STATE METHADONE AUTHORITIES)

TIME: 1:00 PM – 5:00 PM

State Methadone Authorities

The State Methadone Authorities will convene for the presentation of the results of comprehensive research funded by the Robert W. Johnson Foundation and conducted by Deborah Podus, PhD, from the University of California at Los Angeles. This study traces the impact of methadone treatment on a variety of systems since its inception. The SMAs will also have the opportunity to discuss issues of interest to the States.

Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.
The National Drug Abuse Treatment Clinical Trials Network (CTN) is a cooperative undertaking of NIDA, university drug abuse scientists, and community treatment providers in which researchers and practitioners work together to test research-based treatments in community settings. Currently, 17 regional research and training centers are receiving funding, and are linked to more than 125 community treatment programs.

The objectives of the pre-conference session are:

1. Provide an overview of the development and implementation of the National Drug Abuse Treatment Clinical Trials Network
2. Present findings from the “wave 1” clinical trial protocols, describe studies that are currently underway and discuss plans for future studies
3. Discuss the challenges and opportunities associated with programs that blend research and practice, including ethics and confidentiality issues, and lessons that have been learned from the collaboration between academic researchers and community treatment providers
4. Discuss plans for disseminating findings from the CTN studies and training materials and science-based treatment manuals

This session will provide an opportunity for interactive discussion with the conference participants. Handouts and resource materials will be available to the participants in this session.

1:00 pm Overview of the Clinical Trials Network
Betty Tai, PhD
Director, Center for the Clinical Trials Network
National Institute on Drug Abuse, NIH, Bethesda, MD

George Woody, MD
Principal Investigator Delaware Valley Node
Department of Psychiatry, University of Pennsylvania
Philadelphia, PA

2:00 pm Preliminary Findings from Clinical Trials Network Protocols
1. Buprenorphine/naloxone in the detoxification of opiate dependent patients
Walter Ling, MD
Principal Investigator, Pacific Region Node, NIDA CTN
Director, Integrated Substance Abuse Programs, Los Angeles, CA
Professor of Psychiatry and Biobehavioral Sciences, UCLA

2. Motivational enhancement and motivational interviewing to improve treatment engagement and outcome
Sam Ball, PhD
Co-Investigator, New England Node, NIDA CTN
Yale University School of Medicine
Connecticut VA Healthcare Center
New Haven, CT

3. Motivational incentives to enhance drug abuse recovery
Maxine Stitzer, PhD
Principal Investigator, Mid-Atlantic Node, NIDA CTN
Professor, Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, MD

3:00 pm The Clinical Treatment Provider and Policy Perspectives on Participating in Research
Violanda Nunez, LISW
Executive Director, Ayudantes, Inc.
Santa Fe, NM
RISK MANAGEMENT IN THE OTP

Barbara A. M. Maloney, Esq.
Catherine H. O’Neill, Esq.

Time: 1:00 PM – 5:00 PM

Health care risk management programs emerged 30 years ago in direct response to the malpractice crisis of the 1970s. These programs were specifically developed as loss prevention techniques for the risks associated with accidental losses facing health care organizations. AATOD has concluded that methadone treatment programs can benefit from an effective risk management training program, in ways that are similar to the benefits that have accrued to other health care providers. In addition, accreditation has encouraged individualized patient care and developed opportunities for programs to better organize their administrative structure, further supporting risk management as well.

This pre-conference session will introduce OTP practitioners to the key elements of a risk management program and how they can be directly applied to work with methadone treatment programs. Programs will also get the most current information available about leading legal risks to methadone treatment programs and the methodology for developing proactive legal strategies.

The session will consider topics as they apply to specific issues including:

- What happens to the program when adverse events occur
- Scope of risk management
- Common risk identifiers
- Setting priorities, facts to consider
- Risk prevention
- Risk minimization
- Claims management
- Developing proactive legal strategies
- Patients’ confidentiality rights
- Methadone treatment programs’ liability for patients’ actions

Supported by David Szerlip and Associates.
Supported by the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.
PRE-CONFERENCE SESSIONS

Sunday, October 17

EUROPEAN OPIATE ADDICTION TREATMENT ASSOCIATION (EUROPAD)
Heroin Addiction and Related Clinical Problems

TIME: 1:00 PM – 5:00 PM
Chairmen: Icro Maremmani, MD (Pisa, Italy, EU) Marc Reisinger, MD (Brussels, Belgium, EU)

1:00 PM
When Enough is Not Enough. Research and Practice Supporting Prescription of Clinically Effective Doses in Excess of 100 mg in Methadone Maintenance Treatment
M. Shinderman, Chicago, IL, USA

1:20 PM
Attention Deficit Hyperactive Disorder (ADHD) and Addiction Risks (new data)
J. J. Deglon, Geneva, Switzerland

1:40 PM
Psychopathology and Quality of Life in 1-Year Buprenorphine or Methadone Treated Heroin Addicts
I. Maremmani, Pisa, Italy

2:00 PM
Psychopathology and Methadone Maintenance: A 2-Years Follow Up
P.P. Pani, Calgiari, Italy

2:20 PM
IST Project Fact Sheet Intelligent Intra-oral Medicine Delivery Micro-System to Treat Addiction and Chronic Diseases. Funded Under 6th FWP (Sixth Framework Programme)
M. Arieli, Tel Aviv, Israel

2:40 PM
Quality Assessment for MM Patients in Clinical Setting
M. Lovrecic, Ljubljana, Slovenia

3:00 PM
HIV and Drug Abuse Problems in Russia
V. Lisenko, Moscow, Russia

3:20 PM
Comprehensive Methadone Assisted Treatment Model
A. Katchelov, O. Angelova, Sofia, Bulgaria

3:40 PM
Alcohol Abuse in Heroin Addicts
M. Pacini, Pisa, Italy

4:00 PM
The Opening of a New Clinical Institute in France. Results 1-Year After
B. Lepère, M. Sanchez, W. Lowenstein, Paris, France

4:20 PM
Discussion

5:00 PM
End of Forum

In collaboration with Heroin Addiction and Related Clinical Problems and Italian Journal on Addictions.

Welcome Reception

Sunday, October 17, 2004

5:30 PM – 7:30 PM
The Welcome Reception affords all participants the opportunity to make new professional and personal acquaintances, as well as to enjoy some relaxing time with old friends and colleagues not seen for too long. The reception will be held poolside at the Wyndham Palace Resort & Spa.

The Welcome Reception is supported through a grant from Cebert Pharmaceuticals, Inc.
EXHIBIT AND POSTER SESSIONS

Each year, the AATOD annual Conference serves as the central gathering point for the entire methadone treatment field. This year’s 20th Anniversary Conference, in Orlando, Florida, promises to offer an exciting interaction between conference registrants and exhibitors.

This is the only opportunity companies will have to meet with the professionals who are effectively proclaiming opioid dependence as a treatable disease worldwide. The registrants will consist of the decision makers in this field who spend more than $1 billion annually treating the more than 210,000 patients in methadone treatment programs.

To provide exhibitors with steady exposure to conference attendees, all continental breakfasts, coffee breaks and poster sessions will be held exclusively in the exhibit area. This format encourages frequent contact and dialogue between methadone treatment professionals and the exhibiting companies.

Wendy Stevens, Trade Show Manager
Talley Management Group, Inc.
19 Mantua Road
Mt. Royal, NJ 08061
Phone: 856-423-7222 x. 262
Fax: 856-423-3420
wstevens@talley.com

Exhibitors as of July 19, 2004

Accel Software Engineering
Addiction Management Systems, Inc.
Ammon Analytical Laboratory, LLC
BCI Management Systems, Inc.
Bendiner & Schlesinger, Inc.
Braintree Laboratories, Inc.
CARF
Cebert Pharmaceuticals, Inc.
Centre for Addiction and Mental Health
Comstock Computing LLC
Creative Socio-Medics
EastSide Clinic
Friends Medical Laboratory, Inc.
Global Medical Systems, Inc.
International Diagnostic Systems, Corp.
JCAHO
Mallinckrodt Pharmaceuticals
Manisses Communications
National Institute on Drug Abuse
Netalytics, LLC
NOTCA (National Opioid Treatment Clinician Association)
Nutritional Supplements Corporation, Inc.
O. Berk of New England and Kols Containers, Inc.
OraSure Technologies, Inc.
Patient Support & Community Education Project
Reckitt Benckiser
San Diego Reference Laboratory
Scientific Testing Laboratories, Inc.
Secon of New England LLC
Smart Management, Inc.
Substance Abuse and Mental Health Services Administration
Tower Systems
Treatment Software Solutions
VistaPharm, Inc.

International and domestic posters will provide valuable research findings to treatment administrators and clinicians.

Posters are in place at all times

Authors will present their topic on Tuesday from 3:00 PM - 4:30 PM.

Poster Topics Include:

- Evidence-Based Treatments for Opioid Dependence: Clinician Awareness and Program Adoption
- Knowledge and Beliefs about Methadone among Staff Working in a Therapeutic Community
- The Interrelationships between Length of Stay, Methadone Dosage, and Age at an Urban Opioid Treatment Program
- Self-Reported Drug Use: Retrospective Data Collection of Patients Seeking Methadone Treatment
- Prescription Opioid Abuse in Patients Admitted to a Methadone Maintenance Program
- Enhancing the Care of Hospitalized Opioid Dependent Patients
- Co-locating Buprenorphine and Methadone Maintenance Treatment: Challenges and Opportunities
- Role of Attention Deficit Disorder in Methadone Treatment Outcome
- Patterns of Drug Use vs. Frequency of Urine Drug Screens: What is Cost Effective
- Developing a Hepatitis A & B Vaccination Program within an Outpatient Opioid Treatment Program
- The Opioid Treatment Program Accreditation Evaluation: An Overview of the Project and Early Findings
- Hepatitis Immunization Program for North Carolina OTPs: A Follow-Up
- Drug Treatment Demand
- Women and Drugs
- The Assessment and the Comparison of the Clinical and Sociodemographic Characteristics Among Male and Female Heroin Users
- Principles of Safe and Adequate Dosing with Methadone
- Methadone and Cardioprotection
- Connecting the Methadone Treatment Community with Providers Serving Active Users
- Successfully Integrating Treatment Services for Co-Occurring Disorders
- Access to Treatment-Related and Ancillary Services in Opioid Treatment Programs
- Developing a Group Treatment Model that Works for Dual Diagnosed Women in M.T.P.
- Addiction Specialists: Attitudes and Prescribing Patterns with Buprenorphine in the First Year of Its Availability: Results of a National Study
- What Are the Odds? Drug Use Among Pregnant Women in Medication Assisted Treatment

The Monday Continental Breakfast is supported through a grant from Creative Socio-Medics.
The Monday Coffee Break is supported through a grant from San Diego Reference Laboratory.
The Tuesday Continental Breakfast is supported through a grant from Addiction Management Systems, Inc.
The Tuesday Coffee Break is supported through a grant from O. Berk Company of New England and Kols Container, Inc.
The Wednesday Continental Breakfast is supported through a grant from VistaPharm, Inc.
The Goals and Objectives of the American Association for the Treatment of Opioid Dependence 2004 National Conference are:

- To identify and provide new information of critical importance to the field
- To examine and evaluate the implications of new information for clinicians, administrators, and policy makers
- To demonstrate techniques for improving clinical and program administration

OPENING PLENARY SESSION

National Drug Policy: Reducing Demand by Improving Treatment Access

Speakers:

- J. Thomas Payte, MD, Conference Chair, Corporate Medical Director, Colonial Management Group, Orlando, FL
- Mark W. Parrino, MPA, President, American Association for the Treatment of Opioid Dependence, New York, NY
- H. Westley Clark, MD, JD, MPH, CAS, FASAM, Director, Substance Abuse and Mental Health Services Administration/Center for Substance Abuse Treatment, Rockville, MD

The opening plenary session will launch the 20th year of AATOD, providing the latest information to all conference attendees about AATOD's national policies. The plenary session will also provide current information about trends in substance abuse in the state of Florida in addition to focusing on how SAMHSA/CSAT and the White House Office of National Drug Control Policy (ONDCCP) balances the availability of illegal drugs with the need to improve treatment and increase access to care. Dr. H. Westley Clark is one of the nation’s leading voices in promoting the need for evidenced-based treatment practices and the reduction and demand for illegal drugs.

WORKSHOP SESSIONS

Workshops will offer a chance to review the latest treatment data and health care policies, examine their implications for our patients, and strengthen the skills needed to improve the quality of services.

Basic Track Workshop Sessions: A1, B1, C1, D1, E1, and F1

A - 1

Medical Aspects of Methadone

Judith Martin, MD, 14th Street Clinic, Oakland, CA

This workshop is part of the Basic series intended for entry level counselors. It will review the elements of opioid agonist treatment, such as dose, side effects, and duration of MMT. It will cover pharmacologic aspects such as half-life, receptor site, blood level, rapid metabolizer. It is intended to provide a language to engage the patient who is concerned about his or her medication in a therapeutic way.

* NOTE: Basic Track

A - 2

Interface Between Pharmacotherapies and Co-Occurring Disorders in Opioid Dependent Patients

Laura McNicholas, MD, VA Medical Center, Philadelphia, PA; Carlos Tracck, MD, University of Pennsylvania Health System – Treatment Research Division, Philadelphia, PA

This workshop will describe both the historical background to the use of psychoactive medications with patients in opioid maintenance therapy and the current and future outlook for psychopharmacotherapies for patients with co-occurring mental health disorders. Particular emphasis will be placed on the treatment of depressed conditions in opioid dependent patients.

A - 3

Residential Treatment: “What’s Methadone Got to Do With It”

Siara Andrews, PsyD, UCSF-SFGH, San Francisco, CA; Yong Song, PhD, SFGH-Ward 93, San Francisco, CA; Steve Myers, MC, Walden House, San Francisco, CA

This workshop presents research investigating treatment of methadone maintenance patients in residential treatment. This practical workshop will provide ideas for treatment expansion and methodology for building ties between methadone programs and therapeutic communities, with the goal of improving the effectiveness of care for opioid dependence.

A - 4

Maintaining Accreditation: Meeting the Challenges of Compliance

Megan Mane, MPA, Joint Commission on Accreditation of Healthcare Organizations, Littleton, CO; Mary Cesare-Murphy, PhD, Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL

This workshop will provide a review of commonly cited Joint Commission accreditation standards and discuss compliance strategies. Presenters will also share tips for completing the periodic performance review and how to use it as a risk management resource. Finally, presenters will address the use of data to improve program performance.

A - 5

Addressing the Co-Occurring Problems of Intimate Partner Violence and Illicit Drug Use Among Women in MMTPs

(5): Gilbert, CWS, Columbia University, Social Intervention Group, New York, NY; Randy Seewald, MD, Beth Israel Medical Center - MMTR, New York, NY; Brenda M. Ray, NP, Beth Israel Medical Center - MMTR, New York, NY

The purpose of this workshop is to examine the complex relationship between intimate partner violence and illicit drug use among women in MMTPs and to discuss a novel, integrated treatment approach that may address the co-occurring problems of intimate partner violence and illicit drug use in this population.
WORKSHOP SESSIONS

Bereavement: The Culture of Mourning Among Opiate Addicted Individuals
Angela Kirk, PhD, Compdrug Corp., Columbus, OH; Kevin Jay Carroll, MPH, Compdrug Corp., Columbus, OH
This seminar will explore the unique issues faced by bereaved opiate dependent individuals. The stages of grief, an overview of the research and how to identify the readiness for grief work will be presented. In addition, how to implement a grief support group will be discussed.

Growing Your Own Comprehensive Training Program
Robert C. Lambert, MA, Connecticut Counseling Centers, Inc, Norwalk, CT
This workshop will demonstrate how to design and implement a cost-effective in-house training program. The presenter will de-mystify the process of designing a curriculum and give the participants a "nuts and bolts" understanding of how to implement their own training program to meet their unique training needs and credentialing goals.

Treatment on Demand: Learn about Network for the Improvement of Addiction Treatment from the Brandywine Counseling and Acadia Hospital Perspective
James Harrison, LPC, Brandywine Counseling Inc. Wilmington, DE; Scott Farum, MS, Acadia Hospital, Bangor, ME; Lynn Madden, MPA, Acadia Hospital, Bangor, ME
Learn to improve patient access and retention through process improvement, data-driven decision making, and better understanding of the customer. Presenters will discuss their participation in the Paths to Recovery/Strengthening Treatment Access & Retention initiative of the Robert Wood Johnson Foundation and SAMHSA.

HOT TOPIC ROUND TABLES

Hot Topic Round Tables are facilitated discussions that focus on current controversial issues in an informal context. Meet with your colleagues as you learn, challenge, support and share your views with others who may have similar or different opinions, experiences, or interests. Engage in one or more of these facilitated discussions.

- Achieving Accreditation
- MMT and Recovery Stages of Change
- Methadone Anonymous: Positive Benefits to Clinics, Patients and Diminishing the Stigma within the Community at Large
- Administrative Detox: Ethical Dilemmas and Constructive Strategies
- Proactive Responses to Lack of OTP in Correction Facilities
- Buprenorphine Regulations for OTP: Double Standards?
- Retaining Staff: Challenges and Solutions
Monday, October 18, 2004

WORKSHOP SESSIONS

3:30 PM - 5:00 PM

B - 1
Assessment and Treatment Planning for the Clinician
Cynthia Banfield-Weir, LICSW, Community Health Care, Chicopee, MA
As opioid treatment providers meet accreditation standards, clinicians are being asked to demonstrate clinical competence through their ability to complete an assessment and develop a treatment plan that describes an outline for change. This workshop is designed to assist clinicians in assessment and treatment planning.

* Note: Basic Track

B - 2
An NTP Affiliated Office-Based Opiate Treatment (OBOT) Program in a Public Health Setting
Alice Gleghorn, PhD, San Francisco Department of Public Health Community Behavioral Health Services, San Francisco, CA; David Hersh, MD, UCSF, San Francisco, CA; Sharon Kotabe, PharmD, Community Health Network of San Francisco, San Francisco, CA
The San Francisco Department of Public Health OBOT program provides office-based opiate addiction treatment with methadone and buprenorphine to opioid dependent individuals. The presentation will include: program overview; background of its design and implementation; clinical review of buprenorphine/methadone treatment protocols; and issues specific to community-based pharmacy services. Preliminary compliance and outcomes indicators will be discussed.

B - 3
Even Borderlines Get the Blues: Treating the Person, Not Just the Problem
Neil Bomar, MD, Memphis Center for Research and Addiction Treatment, Memphis, TN; Anne Knight, LCSW, Memphis Center for Research and Addiction Treatment, Memphis, TN
This workshop will focus on the importance of using the DSM IV/Axis II in the treatment of opioid dependent individuals. Strategies for treatment planning, realistic goal setting, and clinical tools will be discussed. An overview of the work of Linehan, Kernberg, Beck, and Masterson will also be provided.

B - 4
Prescription Opioid Dependence
Usoa Busto, PhD, Center for Addiction and Mental Health, Toronto, Canada; Steven Clay, DO, Ohio University College of Osteopathic Medicine, Athens, OH; Aaron Gilson, PhD, University of Wisconsin, Madison, WI; Robert Walsh, RAC, NIDA (Facilitator)
Prescription opioid medications can help to improve the quality of life of individuals with severe pain and other medical conditions. However, some of these medications may be abused. The purpose of this workshop is to discuss the nature and extent of the problem of prescription opioid dependence as well as its prevention and treatment.

NIDA Sponsored Workshop

B - 5
Trauma, Addiction and Art Therapy: Connecting the Dots
Sarah Podolin, LSW, Family Center, Philadelphia, PA; Kate Vandergrift, LPC, Family Center, Philadelphia, PA
This workshop will describe how Art Therapy can be an effective tool for working with women who have a history of trauma and abuse. It will discuss how art therapy can be used to develop connections between verbal and non-verbal memory as well as a means of processing traumatic experiences non verbally.

The 2004 Policy Maker’s Luncheon on Monday, October 18, is supported through a grant from Bendiner & Schlesinger, Inc.
Tuesday, October 19, 2004

MIDDLE PLENARY SESSION 8:45 AM - 10:15 AM

Research to Practice: Using Evidence-Based Methods in Community Treatment and Drug Court Settings

Speakers:
- Honorable Reginald Whitehead, Moderator, Circuit Court Judge, Ninth Judicial Circuit, Orlando, FL
- Timothy P. Condon, PhD, Deputy Director, National Institute on Drug Abuse/NIH, Bethesda, MD
- Honorable James McDonough, Drug Policy Coordinator, Executive Office of the Governor, Tallahassee, FL
- Mary Jeanne Kreek, MD, Professor and Head, The Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY

This plenary session will be moderated by Reginald Whitehead, one of the leading drug court judges in the state of Florida, underscoring the increasing partnership between methadone treatment programs and drug courts throughout the United States. Dr. Condon will focus on NIDA’s leading initiatives to improve treatment quality, emerging from the research conducted in methadone treatment programs and other entities within NIDA’s Clinical Trials Network. Mr. McDonough will provide an overview of how Florida is responding to the need for improved prevention and treatment access with a focus on evidence-based practices. Mr. McDonough will also focus his remarks on prescription drug abuse and Florida policies, which are aimed at reducing this increasingly pervasive problem. Dr. Kreek will draw from her long research history and discuss the scientific underpinnings for our field’s work and what to expect for the future.

WORKSHOP SESSIONS 10:30 AM - 12:00 PM

C - 1
Improving Services and Increasing Patient Satisfaction through the Establishment of a Patient Advisory Committee
Ronald Ingram, MSW, Albert Einstein College of Medicine, Bronx, NY; Leonard Gil, Albert Einstein College of Medicine, Bronx, NY; Kathryn Williams, CSW, Albert Einstein College of Medicine, Bronx, NY

This workshop will present a model for establishing Patient Advisory Committees (PACs) in clinic settings; discuss barriers to implementation and potential solutions; and describe how patient input is gathered, analyzed, and used in program planning, performance improvement, organizational advocacy efforts, and resource development.

* Note: Basic Track

C - 2
Pharmacotherapy during Pregnancy: Methadone, Buprenorphine, and Neonatal Abstinence Syndrome
Karol Kaltenbach, PhD, Jefferson Medical College, Philadelphia, PA; John McCarthy, MD, Bi-Valley Medical Clinic, Sacramento, CA; Hendree Jones, PhD, Johns Hopkins University, Baltimore, MD

This workshop will address maternal and infant outcomes utilizing methadone and buprenorphine pharmacotherapy. Presenters will discuss the relationship of maternal methadone dose and neonatal abstinence, maternal and infant outcomes for women treated with up to 190mg of methadone per day, and the safety and efficacy of using buprenorphine during pregnancy.

C - 3
Counseling Strategies for Working with Patients in Advanced Recovery: “Where do we go from here?”
Michael Gaudet, LICSW, Center for Behavioral Health, Johnston, RI; Jamee Lopez, BS, Center for Behavioral Health, Las Vegas, NV; Susan Benassi, LADC, Center for Behavioral Health, Las Vegas, NV

This workshop will explore the dynamics associated with the developmental needs of patients in OMT. Beginning with an overview of the stages of recovery as they interface with phases of treatment, it will focus on the intrapsychic needs of patients who have been in recovery for four or more years.

C - 4
Hepatitis C Treatment: Support, Empowerment and Education
Alain Litwin, MD, Albert Einstein College of Medicine, New York, NY; Irene Soloway, RPA-C, Albert Einstein College of Medicine, Bronx, NY; Frank Medina, PE, Albert Einstein College of Medicine, Bronx, NY

Partner Up! Learn about the power of partnerships between patients and clinicians in the treatment of chronic hepatitis C. We will illustrate the process of implementing a hepatitis C support group and a peer education-training program where ultimately patients emerge as health leaders motivating others in the community to seek treatment.

C - 5
Methadone Maintenance Treatment in Prison: Evaluating a Pilot, Expanding an Intervention
Holly Catania, JD, Beth Israel Medical Center, New York, NY

This workshop will provide an overview of opioid maintenance treatment in prison settings around the world, describe findings and recommendations from evaluation of the first year of a pilot maintenance program in a prison in Puerto Rico, and suggest the implications for expanding prison-based opioid maintenance programs elsewhere.
WORKSHOP SESSIONS

D - 1
Psychiatric Comorbidity
Joan E. Zweben, PhD, Berkeley, CA
This workshop will discuss how counselors can help integrate the treatment of psychiatric disorders into the methadone treatment program. We will discuss addictive behavior and coexisting psychiatric problems, barriers to addressing them, how to educate patients appropriately, how to prioritize treatment tasks, and how to work with physicians around psychotropic medication.
* Note: Basic Track

D - 2
Using Buprenorphine in Opioid Treatment Programs: An Exploration of the Situation
Allan Cohen, MA, Bay Area Addiction, Research and Treatment, Sherman Oaks, CA; Leslie Amass, PhD, Friends Research Institute, Los Angeles, CA; Robert Lubran, MS, CSAT, Rockville, MD
Buprenorphine is the newest medication approved by the FDA for the treatment of opioid dependence. Currently, there are increasing interest and efforts to expand the use of buprenorphine into OTP. This workshop will explore buprenorphine as well as the significant challenges that OTP providers must address to offer buprenorphine as a treatment option in their programs.

D - 3
Reawakening the Creative Spirit, Utilizing Music and Other Art Forms for Advocacy, Outreach and Enhancing the Treatment Experience
Rebecca Boss, MA, LCDP, CODAC, Providence, RI; James Gillen, ACDP, CODAC Providence, RI; Carrie Blake, RCares, Coventry, RI
Our music outreach program, the “CODAC All-Stars,” allows patients to share their recovery in a unique venue that reinforces the belief that they have something to offer. This workshop will demonstrate approaches and activities that promote creative expression leading to enhanced treatment engagement, satisfaction, and improved collaboration with other treatment providers.

D - 4
Illicit Substance Use in Treatment: A Retention-Focused Approach
Sharon Stancliff, MD, Harlem East Life Plan, New York, NY; Joanne King, MS, Harlem East Life Plan, New York, NY; Stuart Steiner, MBA, Harlem East Life Plan, New York, NY
Many patients continue using illicit drugs, sometimes for years. Presenters will provide administrative and medical perspectives on policies promoting retention among inner-city clinic patients with high rates of medical, psychiatric, and social co-morbidities. Case presentations will illustrate applications to dose adjustments, cocaine use, drug injection, and illicit benzodiazepine use.

D - 5
Seeking Safety: A Model for Treating Trauma and Opioid Dependence
Marshall Rosier, MS, Connecticut Counseling Centers, Inc., Waterbury, CT; Alan Nolan, LCSW, Connecticut Counseling Centers, Inc., Waterbury, CT; Diane Heyward, MS, Connecticut Counseling Centers, Inc., Waterbury, CT
This workshop will highlight the essential integration of the Seeking Safety model into the dynamic environment of a methadone maintenance program. An overview of the fundamental principles, treatment goals, central ideas and additional features of this treatment model will be presented.
Introduction to the Awards Program

Please join us for the centerpiece of our Conference – a moving tribute to those colleagues who have been nominated and selected by their peers for extraordinary service in the opioid treatment field. The 2004 American Association for the Treatment of Opioid Dependence National Conference recognizes outstanding contributions to methadone treatment by awarding the Nyswander/Dole Award to the following individuals:

**Cynthia E. Aiken, MS**  
Alaska  
Ms. Aiken has had an extraordinary impact in the treatment of opiate addicted patients in Alaska for 25 years. As the Executive Director of the Narcotic Drug Treatment Center, Ms. Aiken has been instrumental in developing a positive, structured program based on behavioral contracting. For the past 4 years, she has been the co-chair of the Annual School of Addictions, the state’s largest meeting of substance abuse workers. In 1992 she helped found and became the Vice President of the Regional Alcohol and Drug Abuse Counselor Training Program, which is a program that trains substance abuse counselors from all over the state. Ms. Aiken truly believes in the success of methadone treatment and has made her life work to improve the quality of treatment by educating those who hinder this method of treatment.

**Nermana Mehić-Basara, MD**  
Bosnia & Herzegovina  
Dr. Mehić-Basara is the Director of the Public Institute for Alcoholism and Substance Abuse and leader of the methadone maintenance and detoxification program of Canton Sarajevo, Bosnia and Herzegovina. Dr. Mehić-Basara has demonstrated outstanding dedication to the clinical treatment and education of addicted individuals by organizing and conducting specialty courses regarding drug dependence and appropriate treatment regimens, training, and conferences for more than 20 years. She was also actively involved in the creation of the Mental Health Programs before and after the war in Bosnia and Herzegovina. In addition, she is a member of the editorial board of the magazine Odvisnosti – Addiction – Ovisnosti – Zavisnosti and one of the founding members of the establishment of the South Eastern European Addiction Treatment Network.

**David C. Marsh, MD**  
Vancouver, Canada  
Dr. Marsh has been instrumental in establishing and expanding methadone treatment services in Canada for the past 20 years. Dr. Marsh is the Physician Leader of Addiction Medicine at Vancouver Coastal Health Authority and Providence Health Center. For 4 years he headed the Medical Team at the Canadian Centre for Addiction and Mental Health. He was also the principal author of the Best Practices for Methadone Maintenance Therapy on behalf of the Canadian Government. At the University of Toronto, he served as an Assistant Professor in the Department of Psychiatry and Department of Family and Community Medicine. Dr. Marsh has affected the lives of countless patients in gaining access to care throughout Canada.

**Robert Maslansky, MD**  
New York  
Dr. Maslansky is a dedicated, compassionate physician and addiction treatment researcher who is committed to the treatment of opioid dependence and has been a pioneer in the methadone field for more than 35 years. Dr. Maslansky established the first methadone clinic in Minneapolis in 1969 by educating and advocating in the Minneapolis community about the benefits of methadone treatment. He further promoted the treatment of the addicted person as the Director of the Medical Education at Cook County Hospital. Dr. Maslansky was a powerful vocal defender of methadone treatment when it came under intense scrutiny by the former mayor of New York City, in spite of significant political risk. He was also a participant in the development of the New York City Health and Hospital Best Practices Manual. Currently, he is the Medical Director of the Addiction Rehabilitation Program at Bellevue Hospital.

**Laura F. McNicholas, MD**  
Pennsylvania  
Dr. McNicholas joined the Methadone Maintenance Program at the Philadelphia Veterans Administration (VA) Medical Center in 1992 after completing her Psychiatry residency at the University of Pennsylvania, as well as a Fellowship in Clinical Research in Substance Abuse. She assumed the responsibilities of Director of the Center of Excellence for Substance Abuse Treatment and Education in the VA, Philadelphia, as well as the Director of Education for the Penn/VA Center on Studies of Addiction. She has been at the forefront of training clinicians to provide pharmacotherapy for opioid dependence as a faculty member of the Psychiatry Residency Program and active in the research fellowship programs in the VA and the Penn/VA Center. Dr. McNicholas also chaired the Center for Substance Abuse Treatment’s Consensus Panel on Clinical Guidelines for the use of buprenorphine in treatment of opioid dependence and serves as a consultant to the Food and Drug Administration and the Federation of State Medical Boards.
AWARDS BANQUET

Tuesday, October 19, 2004
7:00 PM - 9:30 PM

Michael Rizzi
Rhode Island

Mr. Rizzi has been a treatment professional in the substance abuse service field since 1969. As the President/CEO of CODAC Behavioral Healthcare, Mr. Rizzi has been instrumental in the development and implementation of substance abuse treatment, prevention, and education services including methadone treatment at the Rhode Island State Prison. He is the Chair of the Opiate Treatment Association of Rhode Island. He also serves on the committees to re-write State licensing standards, and local community prevention task forces and is a member of the Board and Treasurer of the American Association for the Treatment of Opioid Dependence (AATOD), chairs AATOD's International Committee, and is AATOD's immediate past representative on the Joint Commission on Accreditation of Healthcare Organizations' Professional and Technical Advisory Committee. He has been a tireless advocate to improve the quality of patient care and a founding member of AATOD.

Richard Schottenfeld, MD
Connecticut

Dr. Schottenfeld serves as a faculty member at the Yale University School of Medicine, as Master of the Davenport College and as Director of the Substance Abuse Center at the Connecticut Mental Health Center. For the past 20 years, Dr. Schottenfeld has dedicated his professional career to the research and treatment of opioid addicts and other substance abusers and has been a tireless advocate for methadone treatment. He was instrumental in integrating science-based research practices into the clinical setting during his tenure at the APT Foundation and is currently the Principal Investigator for six research studies. He serves on the editorial boards of numerous journals and has written extensively, contributing to the body of scientific knowledge, including articles in peer reviewed journals, books and other texts related to drug abuse. His extraordinary efforts have had an incredible impact on the field to improve the quality of patient care.

Robert P. Schwartz, MD
Maryland

Dr. Schwartz has been a constant and commanding proponent of methadone maintenance treatment for 14 years. As a treatment provider, researcher and advocate, he has been successful at increasing access to methadone maintenance treatment in both the community and the jails. He has improved the quality of care provided to methadone maintained patients by integrating primary care and methadone maintenance treatment. As the Program Officer for the Open Society Institute, Dr. Schwartz promotes the welfare of opioid dependent individuals through approving funding for projects that supports the use of methadone and points to best practices in methadone treatment. He is also the Medical Director of Friends Research Institute, where the research projects explore the effectiveness of treatment services and treatment protocols for substance abuse treatment patients.

Marta Torrens, MD
Barcelona, Spain

Dr. Torrens began working in the drug abuse field in 1986. During 1991 when the use of replacement pharmacotherapies became available in Spain, Dr. Torrens was responsible for the methadone program of the Hospital del Mar. This program has been a teaching program for quality methadone maintenance treatment for many years. She has been invited to scientific congresses and meetings as an expert in the field and is also a member of the work group on clinical guidelines for methadone maintenance treatment. Her groundbreaking research on methadone treatment has focused on factors related to retention in treatment, effectiveness of methadone in health related quality of life, clinical usefulness of methadone plasma levels, and psychiatric comorbidity. She has been one of Spain's leading advocates for methadone treatment, especially critical in times of great challenge.

Richard Weisskopf
Illinois

Mr. Weisskopf has been an advocate for professional and accessible methadone maintenance treatment services in Illinois for more than 25 years. Mr. Weisskopf began his career in 1978 as a compliance officer for the Illinois Dangerous Drugs Commission. In 1984, the Commission merged with the Illinois Division of Alcoholism to form the new Illinois Department of Alcoholism and Substance Abuse. With the creation of this new state department, he was appointed both Chief of Licensing for all of Illinois' publicly funded substance abuse treatment programs, and Manager of the Illinois State Methadone Authority. He continues to serve in this capacity and is responsible for administrative oversight of Illinois’ methadone maintenance treatment programs and as the primary liaison for opioid treatment issues. He is a principal in the inception of a mobile methadone unit in the Chicago area and is currently leading a statewide effort to ensure that halfway houses and residential centers accept patients with prescribed methadone. He is respected by treatment providers throughout the state for his consistent advocacy on behalf of the patients.

The 2004 Awards Banquet is supported through a grant from Mallinckrodt, Inc.
E - 1
Ethnic and Cultural Considerations in the Clinical Management of Mental Illness and Substance Abuse
Beny J. Primm, MD, Addiction Research and Treatment Corporation, Brooklyn, NY; Annelle B. Primm, MD, Department of Psychiatry and Behavioral Sciences, John Hopkins Hospital, Baltimore, MD
This presentation will provide participants with an understanding of the complexities of clinical care of mental illness and substance abuse in members of the four major underserved and underrepresented ethnic and racial groups in the United States.
* Note: Basic Track

E - 2
Accreditation of Opioid Treatment Programs: Findings from the Pilot Study
Jennifer J. Kasten, MSW, RTI International, Raleigh, NC
Between 1998 and 2003, CSAT funded a large-scale study to evaluate the impact of accreditation on practices in opioid treatment programs. This workshop will present quality of care findings, accreditation outcomes, organizational changes after pursuing accreditation, and the ability of OTPs to meet the complex demands of opioid maintenance treatment.

E - 3
Evidence-Based Interventions for Difficult Clinical Challenges
Michael McCann, MA, Matrix Institute, Los Angeles, CA; Dan George, Matrix Institute, Los Angeles, CA; Albert Hasson, MSW, Matrix Institute, Los Angeles, CA
HIV risk behaviors, stimulant abuse, and poor attendance are among the most taxing clinical problems counselors must address. Presenters will describe specific interventions including a women’s group targeting HIV risk behaviors, the Matrix Model for stimulant use, and a low cost contingency management procedure to improve attendance.

E - 4
Spirituality and Opioid Treatment
Lisa Cook, LSW, Drug Addiction Services of Hawaii, Honolulu, HI, Marcia Tsue Horiuchi, MSW, Drug Addiction Services of Hawaii, Honolulu, HI; Sarah Kelaui‘ula Carter, Kumu, Drug Addiction Services of Hawaii, Pahoa, HI
OTPs can fall into the trap of holding the regulations and medication management as the core of the program. This workshop will describe culturally based programming and full integration of spirituality in all aspects of management, corporate values, decision making, assessment, treatment interventions, outcomes and program curriculum.

E - 5
A Model for Developing, Implementing and Integrating Patient Advisory Committees in Opioid Treatment Programs
Robert E. Sage, PhD, Addiction Research and Treatment Corporation, Brooklyn, NY; Monica A. Joseph, CSW, Addiction Research and Treatment Corporation, Brooklyn, NY; Ralph J. Savarese, MEd, Addiction Research and Treatment Corporation, Brooklyn, NY
Patient Advisory Committees (PAC) are valuable mechanisms to strengthen managerial and programmatic decision-making, while enhancing patient input and feedback. This workshop demonstrates a practice-based approach that identifies the role and the integration of management, clinical staff and patients in establishing and sustaining the PAC and achieving established objectives.
Wednesday, October 20, 2004

WORKSHOP SESSIONS

F - 1
Motivating the Unmotivated: Increasing Program Compliance Through a Treatment Motivational Track (TMT)
Raymond Pomm, MD, River Region Human Services, Inc., Jacksonville, FL; Gloria Hanania, CAP, River Region Human Services, Inc., Jacksonville, FL; Clara Colon, CAP, River Region Human Services, Inc., Jacksonville, FL
This workshop will review pertinent historical treatment/risk data regarding outcome in a traditional MMTP setting. We will introduce the TMT as an alternative treatment option for those who are not motivated and/or have not satisfactorily progressed in traditional MMTP. Finally, we will review treatment outcomes and patient responses to TMT.
* Note: Basic Track

F - 2
Opioid Dosage Data Base: Continuity of Care in Emergencies
Henry Bartlett, COMPA, Albany, NY; Edward Higgins, MA, J SAS Health Care, Inc., Toms River, NJ; Paul McLaughlin, MA, Hartford Dispensary, Hartford, CT
The lack of a reliable, verifiable regional dosage database seriously compromises emergency readiness. This workshop will describe the stakeholder process (including CSAT, SMAs, and the provider and patient communities from NY, NJ, and CT) and provide recommendations for developing a regional dosage database using an innovative and potentially replicable, secure Web-based system.

F - 3
Accreditation, Advocacy, and Patients in MAT
James P. Connolly, CMA, PA-NAMA and NAMA, Newtown, PA; Rebecca Ballard, CMA, OKNAMA, Tulsa, OK; Carolyn Miranda, CMA, NAMA Southern California, Fountain Valley, CA
Changes in the service environment of MAT, especially accreditation, are affecting relationships of patients, providers, and outside agencies. A panel of NAMA advocates will describe experiences with patient committees, staff advocacy for patient needs, and perceptions of accreditation so far.

F - 4
Using Simple Microsoft Office Tools to Track, Measure, and Report Patient Outcomes
Lawrence O'Toole, MA, Habit Management, Inc., Boston, MA; Carol Wertheimer, PsyD, Melrose-Wakefield Hospital, Lynn, MA
Learn how to integrate Microsoft Excel and Word to track and document patient outcomes, improve treatment, create reports, and meet licensing and accreditation requirements. All participants will receive software that automatically creates tables, graphs, and charts from simple data entered by program staff. Presenters will demonstrate how the software works and how participants can use the software tools within their clinics.

F - 5
Contingency Management Approach: Implementation and Outcomes
Peter Coleman, MS, New York City Health and Hospitals Corporation, New York, NY; Scott Kellogg, PhD, The Rockefeller University, New York, NY; Marylee Bums, MEd, New York City Health and Hospitals Corporation, New York, NY
Presenters will describe how a large municipal hospital system collaborated with researchers to implement a contingency management approach within its methadone treatment programs. Presenters will also discuss the exciting results of this initiative: galvanized and empowered staff, patients with increased motivation to participate in the recovery process, and dramatically changed patient expectations and clinic environments.

CLOSING PLENARY SESSION

Treating the Whole Person: Ensuring the Physical, Mental, and Spiritual Health of Those Recovering from Opioid Dependence

Speakers:
Beny J. Primm, MD
President, Addiction Research and Treatment Corporation, Brooklyn, NY
Annette B. Primm, MD
Department of Psychiatry and Behavioral Sciences, Johns Hopkins Hospital, Baltimore, MD
Addiction affects the biological, psychological and social self of methadone patients who seek recovery. No less important to the life sustaining recovery of methadone patients is the attention to the spiritual self. Dr. Beny Primm and Dr. Annette Primm will provide a comprehensive understanding of how all of these issues interrelate when providing treatment to the patient and increasing the chances of leading to a meaningful life of recovery.
**Wyndham Palace Resort & Spa in the Walt Disney World Resort**

1900 Buena Vista Drive
PO Box 22206
Lake Buena Vista, Florida 32830
407-827-2727
FAX: 407-827-6034
Reservations 407-827-3333 or 1-800-WYNDHAM

The Wyndham Palace Resort & Spa is a paradise conveniently located inside the Walt Disney World® Resort. As an official Downtown Disney® Resort area hotel, it is the perfect Florida destination.

Guests enjoy special privileges: continuous complimentary transportation to all Disney theme parks, dining with favorite Disney characters, access to championship Disney golf courses and more. Universal Studios® Florida and SeaWorld® are just minutes away. Restaurants, shopping, and entertainment are available inside the premises.

Escape to our tropical Recreation Island with three heated swimming pools, whirlpools landscaped for privacy. Take to the net with complimentary lighted tennis courts and sand volleyball. At sunset, savor exceptional cuisine at Disney championship golf courses.

A full-service European-style spa features more than 10,000 square feet of pampered luxury and more than 60 spa treatments, including relaxing massage therapy, soothing body treatments, and rejuvenating facial treatments. The spa also includes a beauty salon, fitness center, private lap pool and whirlpools landscaped for privacy.

Soaring 27 stories above the world’s greatest destination, the Wyndham Palace Resort & Spa is located inside the Walt Disney World® Resort in the heart of the Downtown Disney® area. The hotel offers 1,014 guest rooms and suites that feature amenities such as cordless, two-line phones with voice mail and data port, high-speed Internet access and much more.

Sleeping room rates have been reserved for attendees at a conference rate of $159.00 single/double occupancy. This reduced rate is available until September 22, 2004, depending on availability.

Special Discounts for registrants who book at the Wyndham:

- Guaranteed access to Disney theme parks during peak times
- Preferred tee times at five Walt Disney World 18-hole championship golf courses
- Continuous complimentary bus transportation to the four Disney theme parks:
  - Epcot®
  - Disney-MGM Studios®
  - Disney's Animal Kingdom® Theme Park
  - Downtown Disney®
- Ability to make advance reservations at select Disney restaurants and dinner shows
- Ability to purchase Disney Theme Park tickets at the resort
- Disney character Breakfast buffet at the Watercress Café
- Internet access and a balcony with a spectacular view.
- Relax in a guest room or suite full of delightful touches like high-speed Internet access and a balcony with a spectacular view. Restore body and soul with a workout or world-class treatment in our European-style spa. Outside, enjoy swimming, tennis, and volleyball. At sunset, savor exceptional cuisine at Arthur's 27 on the 27th floor. Stroll to Downtown Disney® for shopping, dazzling entertainment and nightlife, literally across the street from the hotel.

As an Official Hotel of Walt Disney World®, guests enjoy:

- Continuous complimentary bus transportation to the four Walt Disney World® theme parks: Magic Kingdom® Park, Epcot®, Disney-MGM Studios, and Disney's Animal Kingdom® Theme Park
- Preferred tee times at five Walt Disney World 18-hole championship golf courses
- Guaranteed access to Disney theme parks during peak times
- Ability to make advance reservations at select Disney restaurants and dinner shows
- Ability to purchase Disney Theme Park tickets at the resort
- Disney character Breakfast buffet at the Watercress Café

Orlando International Airport (MCO) - Orlando International Airport is approximately 17 miles west of the Wyndham Palace Resort & Spa. Transportation costs will vary, but typical charges are as follows:

<table>
<thead>
<tr>
<th>Type</th>
<th>Cost (One Way)</th>
<th>Cost (Round Trip)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shuttle</td>
<td>$16</td>
<td>$28</td>
</tr>
<tr>
<td>Taxi</td>
<td>$46</td>
<td>$92</td>
</tr>
</tbody>
</table>

TRAVEL INFORMATION

World Travel, Inc. has been designated the Official Travel Coordinator for the 2004 American Association for the Treatment of Opioid Dependence Conference. We recommend that you contact World Travel Group Department at 800-867-2970 (Monday – Friday, 8:00 AM – 5:30 PM EST) for your transportation and car rental needs. Please identify yourself as "American Association for the Treatment of Opioid Dependence" or "AATOD Conference Attendee." World Travel will make all reservations based on the lowest fare available on date of issue.
Regardless of age or vacation wishes, Orlando offers every member of the family a favorite pastime that can be captured forever on film and in fond memories. Orlando captivates visitors with great theme parks and attractions; superb shopping values; art; cultural and historical venues; outdoor adventures; thrilling water parks; diverse dining, entertainment and nightlife; and more.

Central Florida’s rich heritage is most easily found at the Orange County Regional History Center, housed in a 1920s courthouse in the heart of downtown Orlando. Here, the stories of Florida “cracker” cowmen, Seminole Indians, “Tin Can” tourists and Walt Disney come vibrantly to life. Guided tours are also available via tour companies such as Orlando’s Historic & Scenic Tour Company, highlighting the area’s social and cultural heroes and milestones. New Day Enterprises offers African-American heritage tours for groups. Black history is also kept alive via self-guided walking tours of the City of Eatonville, the nation’s oldest incorporated African-American municipality. The Wells’Built Museum of African-American History in downtown Orlando, formerly a hotel frequented by Duke Ellington and Ray Charles, was constructed by Orlando’s first African-American physician, Dr. William Monroe Wells to house guests of his 1920s and 30s hotspot, the South Street Casino.

Lovers of late-Victorian architecture will be delighted by the Historic Waterhouse Residence and Carpenter Shop Museum, which was built in 1884, and the Withers-Maguire House and Museum, which was built in 1888.

If shopping is on the schedule, Orlando has a wealth of stores and boutiques for the more discriminating shopper. Downtown Orlando offers trendy boutiques and restaurants in Thornton Park while Winter Park is perfect for window-shopping and lunching at outdoor cafes on Central Florida’s own “Rodeo Drive” – Park Avenue. At Orlando’s shopping malls, visitors can find the best brands carried at upscale fashion retailers like Neiman Marcus, Bloomingdale’s, Saks Fifth Avenue, Nordstrom, Macy’s, Tiffany’s and Cartier.

As the sun sets on Central Florida, the night is just beginning to heat up in O-Town. Orlando is home to a thriving nightlife scene with options for everyone looking to extend their daytime fun. From ultra-hip bars and high-energy dance clubs to laid-back pubs and multi-venue entertainment complexes, Orlando offers several distinct areas to live it up once the sun goes down.

For more information on “Things To Do” in Orlando, visit Orlando’s official Web site at www.orlandomeetinginfo.com/aatod/, call toll-free at 800-551-0181 (United States and Canada) or 407-363-5872 to speak to an Official Travel Counselor, or visit the Official Visitor Center at 8723 International Drive, Suite 101 on the southeast corner of International Drive and Austrian Row.
General Information

CONFERENCE REGISTRATION
Registration for the American Association for the Treatment of Opioid Dependence (AATOD) Annual Conference can be done on-line by visiting the AATOD website at www.aatod.org or by completing the registration form on page 23 and faxing it to 856-423-3420 or by mailing it to:

AATOD Annual Conference Registration
C/o Talley Management Group, Inc.
19 Mantua Road, Mt. Royal, New Jersey 08061
If faxing your registration, DO NOT mail the original form, doing so may result in duplicate charges to your credit card!

CONFERENCE CONTACTS
Talley Management Group, Inc.
Cheryl Gallagher, Meeting Assistant
19 Mantua Road
Mount Royal, New Jersey 08061
856-423-7222 x. 360
Fax: 856-423-3420
E-mail: aatod@talley.com
Website: www.aatod.org

REGISTRATION
856-423-7222 x. 360

Exhibit Information
Wendy Stevens,
Trade Show Manager
856-423-7222 x. 262
w.stevens@talley.com
Sue Parker, Sales Associate
856-423-7222 x. 227
sparker@talley.com

CONTINUING EDUCATION CREDITS
• AATOD, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB).
• AATOD is an approved provider through the National Association of Alcoholism and Drug Abuse Counselors (NAADAC) (Provider #000218).
• Application to award Continuing Education Units (CEUs) will be submitted to the following organizations:
  New York State Nurses Association’s Council on Continuing Education, which is accredited by the American Nurses’ Credentialing Center’s Commission on Accreditation.
  American Psychological Association to award CEUs to psychologists.
  National Board for Certified Counselors.
REGISTRATION INFORMATION & FEES

HOW TO REGISTER:

Registration can be made by completing the Registration Form, page 23 and mailing or faxing to the address provided or on-line at www.aatod.org and clicking on the ON-LINE REGISTRATION LINK.

<table>
<thead>
<tr>
<th></th>
<th>1 Person from an agency</th>
<th>2 or more from an agency, each</th>
</tr>
</thead>
<tbody>
<tr>
<td>**Full Conference Registration *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 1, 2004 – September 17, 2004</td>
<td>$ 475.00</td>
<td>$ 440.00</td>
</tr>
<tr>
<td>On-Site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 16, 2004</td>
<td>$ 500.00</td>
<td>No Group Discount Applies</td>
</tr>
</tbody>
</table>

* Includes admission to Pre-Conference Sessions (excluding Buprenorphine Course, CMA Training Course, and Clinicians Course), Welcome Reception, all Plenary Sessions, Workshops, daily continental breakfast, and Awards Banquet.

There can be no conference registration fee splitting. Only one discount per conference participant is allowed, including the presenter's discount.

**Group Discounts do not apply for the following categories:**

- **Single Day Registration**
  (Does NOT include Welcome Reception or Awards Banquet) $ 215.00

- **Clinicians Course**
  (Includes Welcome Reception) $ 150.00

- **Additional Awards Banquet Tickets**
  (Must Purchase on site) $ 65.00

- **Additional Welcome Reception Tickets**
  (Must purchase on site) $ 20.00

- **CME/CEU Fees (These fees are not included in full conference registration fee.)**
  - Physicians/Physician’s Assistant/Pharmacists $ 40.00
  - Nurses/Social Workers/Psychologists $ 30.00
  - Counselors $ 20.00

**Special Needs**
The American Association for the Treatment of Opioid Dependence wishes to take steps to ensure that no disabled person is excluded, denied services, segregated or otherwise treated differently than other individuals because of the absence of auxiliary aids and services. If you require any auxiliary aids or services identified in the Americans with Disabilities Act, please indicate so on your registration form.

**Standard Registration Ends September 17, 2004**
STANDARD REGISTRATION FORM

This form not accepted after September 17, 2004

Use one form for each registrant. Photocopies of the form are acceptable. Please print clearly or type or you can register on-line at WWW.AATOD.ORG and click on the ON-LINE REGISTRATION LINK.

Wyndham Palace Resort & Spa, Orlando, FL
October 16-20, 2004

First Name ___________________________ Last Name ___________________________ Degree ___________________________

Department ___________________________ Title ___________________________

Affiliation/Agency/Institution ___________________________

Address ___________________________ ___________________________ ___________________________

City ___________________________ State ___________________________ Zip Code ___________________________ Country ___________________________

Telephone ___________________________ Facsimile ___________________________

Email ___________________________

Please ✓ only the professional designation that applies

☐ Clinical/Medical ☐ Funding Evaluation ☐ Research ☐ Other (Please Specify)

☐ Counseling ☐ Administrative/Management ☐ Policy ___________________________

Please ✓ all that apply

FULL CONFERENCE REGISTRATION May 1, 2004 - September 17, 2004 Fee Enclosed
(Includes Welcome Reception and Awards Banquet)

☐ One person from an agency $ 475.00 $ ______

☐ Two or more from an agency, each $ 440.00 $ ______

☐ Single Day (specify day below) $ 215.00 $ ______

___ Sunday (Does not include Welcome Reception)

___ Monday

___ Tuesday (Does not include Awards Banquet)

___ Wednesday

☐ Clinicians Course $ 150.00 $ ______

CME/CEU fees (These fees are not included in full conference registration fee.)

Please indicate the type of continuing education units you intend to seek:

___ Physicians ___ Physician’s Assistant ___ Pharmacists $ 40.00 $ ______

___ Nurses ___ Social Workers ___ Psychologists $ 30.00 $ ______

___ Counselors ___________________________ TOTAL $ 20.00 $ ______

Please Note: Tickets for the Welcome Reception and the Awards Banquet are not included in the Single Day Registration Fee. Guest tickets for the Welcome Reception may be purchased on site for $ 20.00. Guest Tickets for the Awards Banquet may be purchased on site for $ 65.00.

AATOD, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB).

AATOD is an approved provider through the National Association of Alcoholism and Drug Abuse Counselors (NAADAC) (Provider # 000218).

Application to award Continuing Education Units (CEUs) will be submitted to the following organizations:

New York State Nurses Association's Council on Continuing Education, which is accredited by the American Nurses' Credentialing Center's Commission on Accreditation.

American Psychological Association to award CEUs to psychologists.

National Board for Certified Counselors.
Method of Payment

Name ______________________________________________________________

Registration will not be processed without payment.

☐ I wish to pay my fees by credit card

☐ VISA (13-16 digits) ☐ MasterCard (16 digits) ☐ American Express (15 digits)

Please note: This charge will appear on your statement as “AATOD Conference Registration”

Account Number ____________________________ Expiration Date ____________________________

Name on Card ____________________________

Cardholder Signature ____________________________ Total Fees to be Charged ____________________________

Registrations paid by credit card may be faxed to 856-423-3420. Please keep a copy of your fax confirmation for your record. If faxing, DO NOT mail the original form, doing so may result in duplicate charges to your credit card!

☐ Enclosed is payment by check payable to the American Association for the Treatment of Opioid Dependence.

To ensure prompt processing of your registration, please be sure to remit your check in U.S. dollars and issued by a U.S. correspondent bank. Please check with your local bank before processing payment. Each registrant is responsible for any and all bank charges. A $50.00 processing fee will be charged for checks returned unpaid.

AATOD no longer accepts purchase orders as a form of payment.

Cancellation Policy

If you must cancel your registration, the American Association for the Treatment of Opioid Dependence Registration Department must receive all requests in writing no later than September 17, 2004. All fees paid will be returned less a $50.00 processing fee. THERE WILL BE NO REFUNDS AFTER THE SEPTEMBER 17TH DEADLINE.

Replacement Policy

Replacements will only be processed when requests are received in writing prior to September 17, 2004. There will be NO replacements after that date.

Special Needs

Please indicate any special needs required: ______________________________________________________________________
____________________________________________________________________________________________________________________

To register for the conference, mail or fax the Registration form with your payment in full to:
American Association for the Treatment of Opioid Dependence - Conference 2004
19 Mantua Road
Mt. Royal, New Jersey 08061
FAX: 856-423-3420

Participation in this conference assumes knowledge and authorization of audio and/or video recording of portions of this conference.
Registration will be confirmed in writing within two weeks of receipt of payment.
If you do not receive confirmation by that time, please call 856-423-7222 x 360.
20th Anniversary
National Conference
October 16-20, 2004
Orlando, Florida